数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Stephen Squinto Chairman of the Board 65 未披露 未持股 2021-12-15
Pierluigi Paracchi Chief Executive Officer, Vice Chairman of the Board and General Manager 48 未披露 未持股 2021-12-15
Daniela Bellomo Director 53 未披露 未持股 2021-12-15
Guido Guidi Director 68 未披露 未持股 2021-12-15
Luca Guidotti Director 60 未披露 未持股 2021-12-15
Anthony Marucci Director 59 未披露 未持股 2021-12-15
Roger Abravanel Director 75 未披露 未持股 2021-12-15

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Carlo Russo Chief Medical Officer, Head of Development 68 未披露 未持股 2021-12-15
Pierluigi Paracchi Chief Executive Officer, Vice Chairman of the Board and General Manager 48 未披露 未持股 2021-12-15
Richard B. Slansky Chief Financial Officer 64 未披露 未持股 2021-12-15
Stefania Mazzoleni Scientific Project Manager and Communications Officer 40 未披露 未持股 2021-12-15

董事简历

中英对照 |  中文 |  英文
Stephen Squinto

Stephen Squinto,从2015年4月起担任我们董事会成员。他目前担任OrbiMed(医疗投资公司)的投资合伙人,从2015年1月起在该公司工作。此前,联合创立了一家罕见病生物技术公司-Alexion Pharmaceuticals Inc.;1992年4月-2014年12月担任不同的职位,包括担任执行副总裁和首席全球运营官。他还曾在Regeneron Pharmaceuticals, Inc. 担任不同的职位,在Tulane 大学和Louisiana 州立大学医学院担任学术职位。持有芝加哥Loyola 大学的学士和博士学位。


Stephen Squinto has more than 25 years' experience in the biotech industry and is an Executive Partner of the healthcare investment company OrbiMed Advisors. He was previously CEO of the gene therapy company, Passage Bio, and co-founded Alexion Pharmaceuticals, where he served as Chief Global Operations Officer and Global Head of Research, and held several senior leadership positions at Regeneron Pharmaceuticals. Dr Squinto currently serves on the Board of Directors of several biotech and healthcare companies and has received numerous honors and awards from academic and professional organizations for his scientific work.
Stephen Squinto,从2015年4月起担任我们董事会成员。他目前担任OrbiMed(医疗投资公司)的投资合伙人,从2015年1月起在该公司工作。此前,联合创立了一家罕见病生物技术公司-Alexion Pharmaceuticals Inc.;1992年4月-2014年12月担任不同的职位,包括担任执行副总裁和首席全球运营官。他还曾在Regeneron Pharmaceuticals, Inc. 担任不同的职位,在Tulane 大学和Louisiana 州立大学医学院担任学术职位。持有芝加哥Loyola 大学的学士和博士学位。
Stephen Squinto has more than 25 years' experience in the biotech industry and is an Executive Partner of the healthcare investment company OrbiMed Advisors. He was previously CEO of the gene therapy company, Passage Bio, and co-founded Alexion Pharmaceuticals, where he served as Chief Global Operations Officer and Global Head of Research, and held several senior leadership positions at Regeneron Pharmaceuticals. Dr Squinto currently serves on the Board of Directors of several biotech and healthcare companies and has received numerous honors and awards from academic and professional organizations for his scientific work.
Pierluigi Paracchi

Pierluigi Paracchi在担任生命科学公司的投资者和董事方面拥有超过15年的经验,包括Quantica SGR的创始人兼首席执行官,以及AXò;N Capital,Sofinnova Partners和Aurora Science的高级职位。他也是Ethical Oncology Science的董事会成员和投资者,该公司于2013年被收购,交易总额为4.7亿美元。Pierluigi Paracchi是意大利生物技术发展协会Assobiotec指导委员会的成员。他还任职于自身免疫疾病和癌症公司Altheia Science的董事会,担任医疗设备公司Lipogems International的非执行主席,也是Aurora Science(一家独立的生物技术投资工具)的风险合伙人。


Pierluigi Paracchi has over 15 years of combined experience as an investor and director of life science companies, including as Founder and CEO of Quantica SGR and in senior roles at Axòn Capital, Sofinnova Partners and AurorA Science. He was also a board member and investor in Ethical Oncology Science, which was acquired in 2013 for a total deal of $470 million. Pierluigi Paracchi is a member of the Assobiotec Steering Committee, the Italian Association for the development of biotechnology. He also serves on the Board of Directors of the autoimmune disease and cancer company Altheia Science, as non-executive Chairman at medical device company Lipogems International and is a venture partner with AurorA Science, an independent biotech investment vehicle.
Pierluigi Paracchi在担任生命科学公司的投资者和董事方面拥有超过15年的经验,包括Quantica SGR的创始人兼首席执行官,以及AXò;N Capital,Sofinnova Partners和Aurora Science的高级职位。他也是Ethical Oncology Science的董事会成员和投资者,该公司于2013年被收购,交易总额为4.7亿美元。Pierluigi Paracchi是意大利生物技术发展协会Assobiotec指导委员会的成员。他还任职于自身免疫疾病和癌症公司Altheia Science的董事会,担任医疗设备公司Lipogems International的非执行主席,也是Aurora Science(一家独立的生物技术投资工具)的风险合伙人。
Pierluigi Paracchi has over 15 years of combined experience as an investor and director of life science companies, including as Founder and CEO of Quantica SGR and in senior roles at Axòn Capital, Sofinnova Partners and AurorA Science. He was also a board member and investor in Ethical Oncology Science, which was acquired in 2013 for a total deal of $470 million. Pierluigi Paracchi is a member of the Assobiotec Steering Committee, the Italian Association for the development of biotechnology. He also serves on the Board of Directors of the autoimmune disease and cancer company Altheia Science, as non-executive Chairman at medical device company Lipogems International and is a venture partner with AurorA Science, an independent biotech investment vehicle.
Daniela Bellomo

Daniela Bellomo是San Raffaele Hospital的业务开发主管,在那里她负责生物技术,医疗技术和数字健康研究的技术转让,开发和价值产生。Bellomo博士是San Raffaele剥离Genespire的董事会成员,此前曾在Parco Tecnologico Padano和Biovelocita的董事会任职,也是生物技术和医疗技术领域的几家生命科学初创企业,风险投资和孵化器的顾问。


Daniela Bellomo is Head of Business Development at San Raffaele Hospital, where she oversees technology transfer, development and value generation of research in biotech, medical technology and digital health. Dr. Bellomo is a board member of San Raffaele's spin off Genespire and has previously been on the boards of Parco Tecnologico Padano and BiovelocITA, as well as an advisor to several life science start-ups, venture capital and incubators in the biotech and medical technology field.
Daniela Bellomo是San Raffaele Hospital的业务开发主管,在那里她负责生物技术,医疗技术和数字健康研究的技术转让,开发和价值产生。Bellomo博士是San Raffaele剥离Genespire的董事会成员,此前曾在Parco Tecnologico Padano和Biovelocita的董事会任职,也是生物技术和医疗技术领域的几家生命科学初创企业,风险投资和孵化器的顾问。
Daniela Bellomo is Head of Business Development at San Raffaele Hospital, where she oversees technology transfer, development and value generation of research in biotech, medical technology and digital health. Dr. Bellomo is a board member of San Raffaele's spin off Genespire and has previously been on the boards of Parco Tecnologico Padano and BiovelocITA, as well as an advisor to several life science start-ups, venture capital and incubators in the biotech and medical technology field.
Guido Guidi

Guido Guidi拥有35年在大型制药公司担任全球顶级职位的经验,管理着多达7000名员工,营业额超过8,364亿美元。他曾担任Novartis公司的制药欧盟主管,Novartis EU公司的肿瘤学主管,负责监管主要产品,包括Cosentyx、Entresto、Lucentis、Gilenya、Xolair、Ultibro、Seebri、Galvus和Exforge。


Guido Guidi has 35 years of experience in top global roles in large pharmaceuticals companies, managing up to 7000 employees and a turnover of more than €7 billion. He was previously Head of Pharma EU at Novartis, Head of Oncology at Novartis EU, overseeing major products including Cosentyx, Entresto, Lucentis, Gilenya, Xolair, Ultibro, Seebri, Galvus and Exforge.
Guido Guidi拥有35年在大型制药公司担任全球顶级职位的经验,管理着多达7000名员工,营业额超过8,364亿美元。他曾担任Novartis公司的制药欧盟主管,Novartis EU公司的肿瘤学主管,负责监管主要产品,包括Cosentyx、Entresto、Lucentis、Gilenya、Xolair、Ultibro、Seebri、Galvus和Exforge。
Guido Guidi has 35 years of experience in top global roles in large pharmaceuticals companies, managing up to 7000 employees and a turnover of more than €7 billion. He was previously Head of Pharma EU at Novartis, Head of Oncology at Novartis EU, overseeing major products including Cosentyx, Entresto, Lucentis, Gilenya, Xolair, Ultibro, Seebri, Galvus and Exforge.
Luca Guidotti

Luca Guidotti是一位在病毒性肝炎领域享誉国际的实验病理学家。Guidotti博士在加利福尼亚州拉霍亚的斯克里普斯研究所担任了20多年的教师,他目前担任米兰圣拉斐尔医院的副科学主任。他在著名的科学期刊上发表了作品,包括《细胞》,《自然》,《科学》,《自然医学》,《临床研究杂志》和《实验医学杂志》。


Luca Guidotti is an experimental pathologist renowned internationally in the field of viral hepatitis. Dr. Guidotti spent more than 20 years as a Faculty of the Scripps Research Institute in La Jolla, California and he currently serves as Deputy Scientific Director of San Raffaele Hospital, Milan. He has published works in prestigious scientific journals including Cell, Nature, Science, Nature Medicine, Journal of Clinical Investigation and Journal of Experimental Medicine.
Luca Guidotti是一位在病毒性肝炎领域享誉国际的实验病理学家。Guidotti博士在加利福尼亚州拉霍亚的斯克里普斯研究所担任了20多年的教师,他目前担任米兰圣拉斐尔医院的副科学主任。他在著名的科学期刊上发表了作品,包括《细胞》,《自然》,《科学》,《自然医学》,《临床研究杂志》和《实验医学杂志》。
Luca Guidotti is an experimental pathologist renowned internationally in the field of viral hepatitis. Dr. Guidotti spent more than 20 years as a Faculty of the Scripps Research Institute in La Jolla, California and he currently serves as Deputy Scientific Director of San Raffaele Hospital, Milan. He has published works in prestigious scientific journals including Cell, Nature, Science, Nature Medicine, Journal of Clinical Investigation and Journal of Experimental Medicine.
Anthony Marucci

Anthony Marucci是一位经验丰富的生命科学和上市公司领导者,在他30年的经验中,他在多个组织中筹集了17亿美元的资本。他目前是Celldex Therapeutics的总裁兼首席执行官,该公司是他于2004年共同创立的,开发靶向疗法,包括免疫疗法和其他靶向生物制剂。在创立Celldex之前,他是Medarex的财务主管,Celldex是从Medarex分离出来的,他拥有哥伦比亚大学的工商管理硕士学位和布朗大学的MHL学位。


Anthony Marucci is a seasoned life sciences and public company leader who has raised $1.7 billion in capital in multiple organizations over his 30 years' experience. He is currently President and CEO of Celldex Therapeutics, the company he co-founded in 2004 and which develops targeted therapeutics, including immunotherapies and other targeted biologics. Prior to founding Celldex, he was Treasurer at Medarex, from which Celldex was spun out, and he holds an MBA from Columbia University and a MHL from Brown University.
Anthony Marucci是一位经验丰富的生命科学和上市公司领导者,在他30年的经验中,他在多个组织中筹集了17亿美元的资本。他目前是Celldex Therapeutics的总裁兼首席执行官,该公司是他于2004年共同创立的,开发靶向疗法,包括免疫疗法和其他靶向生物制剂。在创立Celldex之前,他是Medarex的财务主管,Celldex是从Medarex分离出来的,他拥有哥伦比亚大学的工商管理硕士学位和布朗大学的MHL学位。
Anthony Marucci is a seasoned life sciences and public company leader who has raised $1.7 billion in capital in multiple organizations over his 30 years' experience. He is currently President and CEO of Celldex Therapeutics, the company he co-founded in 2004 and which develops targeted therapeutics, including immunotherapies and other targeted biologics. Prior to founding Celldex, he was Treasurer at Medarex, from which Celldex was spun out, and he holds an MBA from Columbia University and a MHL from Brown University.
Roger Abravanel

Roger Abravanel,自2006年担任董事。1972年至2006年6月,他工作于McKinsey & Company 。Abravanel先生也参与国际咨询项目,在战略,组织和业务发展的问题的建议。他获得了Politecnico di Milano 工程学位并以优秀成绩获得枫丹白露INSEAD工商管理硕士学位。他是好几个研究和商业组织文章的作者。他是Teva Pharmaceutical Industries LTDBanca Nazionale del Lavoro S.p.A., Admiral Group Plc., Coesia S.p.A. and Esselunga S.p.A。的董事会成员。


Roger Abravanel worked at McKinsey & Company for 34 years as a consultant for Italian and multinational corporations in Europe, the United States and the Far East, and is now an emeritus director. He is a former board member of Luxottica, COFIDE, Teva and Admiral, is currently Chairman of the INSEAD's advisory group in Italy and is the author of several best-selling business books.
Roger Abravanel,自2006年担任董事。1972年至2006年6月,他工作于McKinsey & Company 。Abravanel先生也参与国际咨询项目,在战略,组织和业务发展的问题的建议。他获得了Politecnico di Milano 工程学位并以优秀成绩获得枫丹白露INSEAD工商管理硕士学位。他是好几个研究和商业组织文章的作者。他是Teva Pharmaceutical Industries LTDBanca Nazionale del Lavoro S.p.A., Admiral Group Plc., Coesia S.p.A. and Esselunga S.p.A。的董事会成员。
Roger Abravanel worked at McKinsey & Company for 34 years as a consultant for Italian and multinational corporations in Europe, the United States and the Far East, and is now an emeritus director. He is a former board member of Luxottica, COFIDE, Teva and Admiral, is currently Chairman of the INSEAD's advisory group in Italy and is the author of several best-selling business books.

高管简历

中英对照 |  中文 |  英文
Carlo Russo

Carlo Russo自2015年7月起担任公司执行副总裁和首席医疗官。加入Annapurna之前,Russo自2005年起在GlaxoSmithKline, plc任职,最近的职位是担任多个研发领域的高级副总裁,包括Alternative Development Programs主管;Cardiovascular & Metabolic Medicine Development Center主管;Biopharm Unit创始成员和开发主管;Rare Diseases Unit研发主管。在他的领导下,GlaxoSmithKline申请并发行治疗Type 2糖尿病的U.S. Tanzeum以及治疗狼疮的Benlysta;最近申请欧洲的Market Authorization Application为严重联合免疫缺陷综合症ADA-SCID病人进行基因疗法。之前,Russo曾担任VaxInnate Corporation(一家疫苗公司,为防止流感开发产品)总裁和首席执行官;Vaccines and Biologics全球战略监督开发主管,包括Merck Research Laboratories的人类乳头状瘤病毒和轮状病毒疫苗。他在Cornell University拥有学术任命,是72篇专业论文的作者。Russo持有the University of Genoa Medical School医学硕士学位。


Carlo Russo has extensive experience as a biotech executive focused on medical affairs and research and development. He has served as Head of Development of GSK's R&D Biopharm and Rare Disease Units and the Cardiovascular Metabolic Center. Previously, Dr. Russo served as an Executive VP and CMO of Adverum, CMO & Head of Research & Development of Annapurna and President and CEO of VaxInnate Corporation, among other senior roles. Dr Russo holds a number of senior positions at research institutions, including Cornell University Medical College, Columbia University and Scripps Research Institute. He holds his MD and Board Certification in Hematology from the University of Genoa Medical School and is the author of more than 70 scientific publications.
Carlo Russo自2015年7月起担任公司执行副总裁和首席医疗官。加入Annapurna之前,Russo自2005年起在GlaxoSmithKline, plc任职,最近的职位是担任多个研发领域的高级副总裁,包括Alternative Development Programs主管;Cardiovascular & Metabolic Medicine Development Center主管;Biopharm Unit创始成员和开发主管;Rare Diseases Unit研发主管。在他的领导下,GlaxoSmithKline申请并发行治疗Type 2糖尿病的U.S. Tanzeum以及治疗狼疮的Benlysta;最近申请欧洲的Market Authorization Application为严重联合免疫缺陷综合症ADA-SCID病人进行基因疗法。之前,Russo曾担任VaxInnate Corporation(一家疫苗公司,为防止流感开发产品)总裁和首席执行官;Vaccines and Biologics全球战略监督开发主管,包括Merck Research Laboratories的人类乳头状瘤病毒和轮状病毒疫苗。他在Cornell University拥有学术任命,是72篇专业论文的作者。Russo持有the University of Genoa Medical School医学硕士学位。
Carlo Russo has extensive experience as a biotech executive focused on medical affairs and research and development. He has served as Head of Development of GSK's R&D Biopharm and Rare Disease Units and the Cardiovascular Metabolic Center. Previously, Dr. Russo served as an Executive VP and CMO of Adverum, CMO & Head of Research & Development of Annapurna and President and CEO of VaxInnate Corporation, among other senior roles. Dr Russo holds a number of senior positions at research institutions, including Cornell University Medical College, Columbia University and Scripps Research Institute. He holds his MD and Board Certification in Hematology from the University of Genoa Medical School and is the author of more than 70 scientific publications.
Pierluigi Paracchi

Pierluigi Paracchi在担任生命科学公司的投资者和董事方面拥有超过15年的经验,包括Quantica SGR的创始人兼首席执行官,以及AXò;N Capital,Sofinnova Partners和Aurora Science的高级职位。他也是Ethical Oncology Science的董事会成员和投资者,该公司于2013年被收购,交易总额为4.7亿美元。Pierluigi Paracchi是意大利生物技术发展协会Assobiotec指导委员会的成员。他还任职于自身免疫疾病和癌症公司Altheia Science的董事会,担任医疗设备公司Lipogems International的非执行主席,也是Aurora Science(一家独立的生物技术投资工具)的风险合伙人。


Pierluigi Paracchi has over 15 years of combined experience as an investor and director of life science companies, including as Founder and CEO of Quantica SGR and in senior roles at Axòn Capital, Sofinnova Partners and AurorA Science. He was also a board member and investor in Ethical Oncology Science, which was acquired in 2013 for a total deal of $470 million. Pierluigi Paracchi is a member of the Assobiotec Steering Committee, the Italian Association for the development of biotechnology. He also serves on the Board of Directors of the autoimmune disease and cancer company Altheia Science, as non-executive Chairman at medical device company Lipogems International and is a venture partner with AurorA Science, an independent biotech investment vehicle.
Pierluigi Paracchi在担任生命科学公司的投资者和董事方面拥有超过15年的经验,包括Quantica SGR的创始人兼首席执行官,以及AXò;N Capital,Sofinnova Partners和Aurora Science的高级职位。他也是Ethical Oncology Science的董事会成员和投资者,该公司于2013年被收购,交易总额为4.7亿美元。Pierluigi Paracchi是意大利生物技术发展协会Assobiotec指导委员会的成员。他还任职于自身免疫疾病和癌症公司Altheia Science的董事会,担任医疗设备公司Lipogems International的非执行主席,也是Aurora Science(一家独立的生物技术投资工具)的风险合伙人。
Pierluigi Paracchi has over 15 years of combined experience as an investor and director of life science companies, including as Founder and CEO of Quantica SGR and in senior roles at Axòn Capital, Sofinnova Partners and AurorA Science. He was also a board member and investor in Ethical Oncology Science, which was acquired in 2013 for a total deal of $470 million. Pierluigi Paracchi is a member of the Assobiotec Steering Committee, the Italian Association for the development of biotechnology. He also serves on the Board of Directors of the autoimmune disease and cancer company Altheia Science, as non-executive Chairman at medical device company Lipogems International and is a venture partner with AurorA Science, an independent biotech investment vehicle.
Richard B. Slansky

Richard B. Slansky是一名高级财务执行官,拥有30多年的经验,担任多个生物制药、诊断和生命科学公司的首席财务官,包括OncoSec Medical、Biological Dynamics和GenMark Diagnostics。他的经验跨越公共和私人医疗保健和技术公司,处于不同的增长阶段,从收入到商业。他一直负责财务和运营团队的战略愿景和监督,组织领导和创造最大的利益相关者价值。他还担任几家私人公司的董事会成员,包括Nuclear RNA Networks,这是一家早期RNA基因转录疗法公司。


Richard B. Slansky is a senior financial executive with more than 30 years of experience as Chief Financial Officer in various biopharmaceutical, diagnostic and life science companies, including OncoSec Medical, Biological Dynamics and GenMark Diagnostics. His experience spans across public and private healthcare and technology companies at various stages of growth, pre-revenue to commercial. He has been responsible for strategic vision and oversight of financial and operational teams, organizational leadership and creating maximum stakeholder value. He also serves on the Board of Directors of several private companies, including Nuclear RNA Networks, an early-stage RNA gene transcription therapeutics company.
Richard B. Slansky是一名高级财务执行官,拥有30多年的经验,担任多个生物制药、诊断和生命科学公司的首席财务官,包括OncoSec Medical、Biological Dynamics和GenMark Diagnostics。他的经验跨越公共和私人医疗保健和技术公司,处于不同的增长阶段,从收入到商业。他一直负责财务和运营团队的战略愿景和监督,组织领导和创造最大的利益相关者价值。他还担任几家私人公司的董事会成员,包括Nuclear RNA Networks,这是一家早期RNA基因转录疗法公司。
Richard B. Slansky is a senior financial executive with more than 30 years of experience as Chief Financial Officer in various biopharmaceutical, diagnostic and life science companies, including OncoSec Medical, Biological Dynamics and GenMark Diagnostics. His experience spans across public and private healthcare and technology companies at various stages of growth, pre-revenue to commercial. He has been responsible for strategic vision and oversight of financial and operational teams, organizational leadership and creating maximum stakeholder value. He also serves on the Board of Directors of several private companies, including Nuclear RNA Networks, an early-stage RNA gene transcription therapeutics company.
Stefania Mazzoleni

Stefania Mazzoleni管理和监督肿瘤适应症中并行免疫基因疗法研究的科学开发,并为投资者互动提供科学支持。Mazzoleni博士在生命科学研究与开发、肿瘤学和项目管理方面拥有超过15年的经验,包括在圣拉斐尔医院工作期间获得的超过4年的药物开发以及细胞和基因治疗经验,国家分子遗传学和制药学研究所(Nerviano Medical Sciences)。Mazzoleni博士于2005年获得医学生物技术硕士学位,拥有San Raffaele Vita-Salute大学的分子和细胞生物学博士学位,拥有药学和药物肿瘤学的二级职业硕士学位,并且是欧洲肿瘤免疫学会的成员。


Stefania Mazzoleni manages and oversees the scientific development of parallel immuno-gene therapy studies in oncology indications and provides scientific support for investor interactions. Dr. Mazzoleni has more than 15 years' experience in life science research and development, oncology and project management, including over 4 years of drug development and cell and gene therapy experience acquired while working at various academic institutions San Raffaele Hospital, National Institute of Molecular Genetics and pharmaceutics (Nerviano Medical Sciences). Dr. Mazzoleni received a MSc in Medical Biotechnology in 2005 holds a PhD in Molecular and Cellular Biology from San Raffaele Vita-Salute University, has a second level vocational Master's in Pharmacy and Pharmaceutical Oncology and is a member of the European Academy of Tumor Immunology.
Stefania Mazzoleni管理和监督肿瘤适应症中并行免疫基因疗法研究的科学开发,并为投资者互动提供科学支持。Mazzoleni博士在生命科学研究与开发、肿瘤学和项目管理方面拥有超过15年的经验,包括在圣拉斐尔医院工作期间获得的超过4年的药物开发以及细胞和基因治疗经验,国家分子遗传学和制药学研究所(Nerviano Medical Sciences)。Mazzoleni博士于2005年获得医学生物技术硕士学位,拥有San Raffaele Vita-Salute大学的分子和细胞生物学博士学位,拥有药学和药物肿瘤学的二级职业硕士学位,并且是欧洲肿瘤免疫学会的成员。
Stefania Mazzoleni manages and oversees the scientific development of parallel immuno-gene therapy studies in oncology indications and provides scientific support for investor interactions. Dr. Mazzoleni has more than 15 years' experience in life science research and development, oncology and project management, including over 4 years of drug development and cell and gene therapy experience acquired while working at various academic institutions San Raffaele Hospital, National Institute of Molecular Genetics and pharmaceutics (Nerviano Medical Sciences). Dr. Mazzoleni received a MSc in Medical Biotechnology in 2005 holds a PhD in Molecular and Cellular Biology from San Raffaele Vita-Salute University, has a second level vocational Master's in Pharmacy and Pharmaceutical Oncology and is a member of the European Academy of Tumor Immunology.